论文部分内容阅读
目的 对比研究Ⅲ期非小细胞肺癌放射治疗 +化疗综合治疗的疗效 ,探讨更有效的治疗方式。方法 6 0例Ⅲ期非小细胞肺癌患者均分至 2个组。单放组采用常规分割 ,总量 6 0～ 70Gy ,6～ 7周 ,综合治疗组采用放射治疗加化疗 ,化疗采用以顺铂为主的化疗方案 ,在放射治疗同时或前中后进行 ,最少 2个周期。结果 2个组治疗后完全缓解率 :单放组为 2 0 % ,综合组为 43% ;病情进展率 :单放组为 10 % ,综合组为 7% ,2个组近期疗效差异无显著性意义 (χ2 =4.11,P =0 .2 5 )。 1、2、3年生存率单放组分别为 42 .4%、15 .7%、7.8% ,综合组分别为 6 8.1%、37.8%、18.9% ;中位生存期单放组为 8个月 ,综合组为 15个月。 2个组生存率差异有显著性意义 (χ2 值分别为 4.2 4、4.15、3.96 ,P值均 <0 .0 5 )。综合组副作用大于单放组 (t=4.318,P <0 .0 1)。结论 放射治疗 +化疗综合治疗明显提高Ⅲ期非小细胞肺癌的 1、2、3年生存率 ,更有效的放射治疗 +化疗结合方式为放射治疗 +化疗同时或交叉进行
Objective To compare the efficacy of radiotherapy + chemotherapy in the treatment of stage III non-small cell lung cancer (NSCLC) and explore more effective treatments. Methods Sixty patients with stage III NSCLC were divided equally into 2 groups. The radiotherapy group was divided into routine groups, totaling 60-70 Gy, for 6-7 weeks. Radiotherapy and chemotherapy were used in the comprehensive treatment group. Chemotherapy regimen based on cisplatin was used for chemotherapy. At the same time or before and after radiation therapy, at least 2 cycles. Results The complete remission rate after treatment in 2 groups was 20% in the radiotherapy group and 43% in the integrated group; the progression rate of the disease was 10% in the radiotherapy group and 7% in the integrated group. There was no significant difference in the curative effect between the two groups. Significance (χ 2 =4.11, P =0.25). The 1-, 2-, and 3-year survival rates for the radiotherapy group were 42.4%, 15.7%, and 7.8%, respectively, for the comprehensive group, which was 6 8.1%, 37.8%, and 18.9%; the median survival period for the radiotherapy group was 8 Month, the comprehensive group is 15 months. There was a significant difference in the survival rate between the two groups (χ2 values were 4.2 4, 4.15, and 3.96, respectively; P values were <0.05). The side effects of the integrated group were greater than that of the single-release group (t=4.318, P < 0.01). Conclusion Radiotherapy combined with chemotherapy can significantly improve the 1-, 2-, and 3-year survival rate of stage III NSCLC. More effective radiation therapy + chemotherapy combined with radiation therapy + chemotherapy can be performed at the same time or crossover.